Comparison of PENG Block and FICB in Hip Fracture Patients
Launched by ASAN MEDICAL CENTER · Dec 15, 2020
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ASA PS 1-4
- • age: ≥19
- • baseline pain score (associated with hip fracture): ≥4
- Exclusion Criteria:
- • patients who do not agree to participate in this study
- • patients with uncontrolled hypertension, hyperthyroidism, severe dementia
- • allergic to ropivacaine
- • contraindicated to spinal anesthesia due to coagulopathy, severe aortic stenosis/mitral stenosis, or active infection on lumbar region
- • patients who are considered ineligible with any other reason by investigators
About Asan Medical Center
Asan Medical Center, located in Seoul, South Korea, is a leading healthcare institution renowned for its commitment to advanced medical research and patient care. With a focus on innovative clinical trials, the center aims to enhance healthcare outcomes through rigorous scientific investigation and collaboration. Asan Medical Center is equipped with state-of-the-art facilities and a multidisciplinary team of experts dedicated to exploring new therapeutic approaches across various medical fields. Its robust infrastructure supports a wide range of clinical studies, contributing significantly to the global medical community's understanding of diseases and treatment efficacy.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Patients applied
Trial Officials
Won Uk Koh, MD, PhD
Principal Investigator
Asan Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials